-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chronic spontaneous urticaria (CSU) is characterized by the development of wind masses, angioedema, or both without obvious external causes for more than six weeks
Febutinib is an oral, potent, highly selective, and reversible BTK inhibitor, which may be effective in the treatment of CSU
Recently, a research article was published in the top medical journal Nature Medicine.
The primary endpoint of the study was the change from baseline to week 8 in the urticaria activity score over 7 days (UAS7)
Compared with the placebo group in the 50 mg febutinib treatment group, the 200 mg twice a day and 150 mg febutinib treatment group once a day reached the primary end point, that is, the dose-dependent improvement of UAS7 at week 8
Thus, these results support the potential therapeutic effect of BTK inhibitors in CSU refractory to antihistamines
These results support the potential therapeutic effect of BTK inhibitors in CSU refractory to antihistamines
Original source:
Original source:Martin Metz,et al.